Retinal Vein Changes in Patients with High-risk Proliferative Diabetic Retinopathy Treated with Conbercept and Panretinal Photocoagulation Co-therapy: a Cohort Study

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Sep 11

PMID 37693359

Authors

Mingwei Si

Yuan Tao

Ziniu Zhang

Hui Zhao

Wenxuan Cui

Mengyao Yang

Hong Wang

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy.

Methods: A retrospective analysis was conducted on data from patients with high-risk PDR who received specific treatment and were followed up for 24 months. Among 82 patients with high-risk PDR, 50 eyes received PRP combined with IVC, whereas 32 eyes received PRP alone. During the 24-month follow-up period, changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), retinal vein diameter, number of microaneurysms (MA), neovascularization (NV) area, hard exudate (HE) area, size of the foveal avascular zone (FAZ), superficial capillary plexus (SCP) blood flow density, and adverse effects were recorded and compared between the two groups at baseline and at 6, 12, 18, and 24 months after treatment. The relationship between each observation index and vein diameter was also analyzed.

Results: During the 24-month follow up, significant improvements in the BCVA, CFT, retinal vein diameter, number of MAs, NV area, HE area, FAZ, and SCP were observed in the IVC+PRP group after treatment. The PRP group only showed significant reductions in NV and HE areas. The IVC+PRP group showed significant superiority over the PRP group in improving the vein diameter, number of MA, and HE area. However, no statistically significant difference in NV area reduction was found between the groups.

Conclusion: In the treatment of high-risk PDR, IVC+PRP therapy has a significant advantage over PRP monotherapy. IVC+PRP therapy may reverse diabetes-induced retinal vein changes, restoring morphology and function.

Citing Articles

Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review.

Gawecki M, Kicinski K, Bianco L, Battaglia Parodi M Diagnostics (Basel). 2024; 14(1).

PMID: 38201340 PMC: 10802854. DOI: 10.3390/diagnostics14010031.

References

Lee H, Lee M, Chung H, Kim H . QUANTIFICATION OF RETINAL VESSEL TORTUOSITY IN DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2017; 38(5):976-985. DOI: 10.1097/IAE.0000000000001618. View

Moutray T, Evans J, Lois N, Armstrong D, Peto T, Azuara-Blanco A . Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018; 3:CD012314. PMC: 6494342. DOI: 10.1002/14651858.CD012314.pub2. View

Tolentino M, McLeod D, Taomoto M, Otsuji T, Adamis A, Lutty G . Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002; 133(3):373-85. DOI: 10.1016/s0002-9394(01)01381-2. View

Blindbaek S, Peto T, Grauslund J . Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial. Acta Ophthalmol. 2019; 98(4):353-359. DOI: 10.1111/aos.14278. View

Sun Y, Qi H . A comparison between the therapeutic effects of Conbercept combined with panretinal photocoagulation and panretinal photocoagulation monotherapy for high-risk proliferative diabetic retinopathy. Front Endocrinol (Lausanne). 2023; 13:1038757. PMC: 9880417. DOI: 10.3389/fendo.2022.1038757. View

Klein R, Myers C, Lee K, Gangnon R, Klein B . Changes in retinal vessel diameter and incidence and progression of diabetic retinopathy. Arch Ophthalmol. 2012; 130(6):749-55. PMC: 3357449. DOI: 10.1001/archophthalmol.2011.2560. View

Zhao H, Wang J, Li S, Bao Y, Zheng X, Tao Y . Retinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy. Front Med (Lausanne). 2023; 10:1090964. PMC: 10034169. DOI: 10.3389/fmed.2023.1090964. View

Martinez-Zapata M, Salvador I, Marti-Carvajal A, Pijoan J, Cordero J, Ponomarev D . Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2023; 3:CD008721. PMC: 10026605. DOI: 10.1002/14651858.CD008721.pub3. View

Lee R, Wong T, Sabanayagam C . Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015; 2:17. PMC: 4657234. DOI: 10.1186/s40662-015-0026-2. View

10.

Fonseca R, Dantas M . Retinal venous beading associated with recurrent branch vein occlusion. Can J Ophthalmol. 2002; 37(3):182-3. DOI: 10.1016/s0008-4182(02)80062-x. View

11.

Levin A, Rusu I, Orlin A, Gupta M, Coombs P, DAmico D . Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin Ophthalmol. 2017; 11:193-200. PMC: 5268366. DOI: 10.2147/OPTH.S118807. View

12.

Fong D, Segal P, Myers F, Ferris F, Hubbard L, Davis M . Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1997; 115(7):873-7. DOI: 10.1001/archopht.1997.01100160043006. View

13.

Shen Y, Wang H, Fang J, Liu K, Xu X . Novel insights into the mechanisms of hard exudate in diabetic retinopathy: Findings of serum lipidomic and metabolomics profiling. Heliyon. 2023; 9(4):e15123. PMC: 10119565. DOI: 10.1016/j.heliyon.2023.e15123. View

14.

Sun J, Glassman A, Beaulieu W, Stockdale C, Bressler N, Flaxel C . Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2018; 126(1):87-95. PMC: 6916649. DOI: 10.1016/j.ophtha.2018.08.001. View

15.

Nicholson L, Crosby-Nwaobi R, Vasconcelos J, Prevost A, Ramu J, Riddell A . Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. Invest Ophthalmol Vis Sci. 2018; 59(10):4277-4284. PMC: 6108778. DOI: 10.1167/iovs.17-23509. View

16.

Domalpally A, Ip M, Ehrlich J . Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology. 2015; 122(4):779-86. DOI: 10.1016/j.ophtha.2014.10.028. View

17.

Liu K, Wang H, He W, Ye J, Song Y, Wang Y . Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2021; 106(10):1436-1443. PMC: 9510409. DOI: 10.1136/bjophthalmol-2020-318690. View

18.

. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987; 27(4):239-53. DOI: 10.1097/00004397-198702740-00004. View

19.

Huang J, Li X, Li M, Li S, Xiao W, Chen X . Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012; 14(7):644-53. DOI: 10.1111/j.1463-1326.2012.01584.x. View

20.

Filho J, Messias A, Almeida F, Ribeiro J, Costa R, Scott I . Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011; 89(7):e567-72. DOI: 10.1111/j.1755-3768.2011.02184.x. View